Treatment of Pulmonary Arterial Hypertension: A Preliminary Decision Analysis

Chest

Volumn 124, Issue 6, 2003, Pages 2087-2092

  Highland, Kristin B ^a,b   Strange, Charlie ^a   Mazur, Joe ^a   Simpson, Kit N ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Bosentan; Decision analysis; Epoprostenol; Pulmonary arterial hypertension; Treprostinil

Indexed keywords

BOSENTAN; PROSTACYCLIN; UNIPROST;

ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEATH; FUNCTIONAL ASSESSMENT; HEALTH STATUS; HUMAN; MEDICAL DECISION MAKING; MEDICARE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROBABILITY; PULMONARY HYPERTENSION; QUALITY ADJUSTED LIFE YEAR; SIDE EFFECT; SURVIVAL RATE; TACHYPHYLAXIS; VIRTUAL REALITY; WALKING;

EID: 0346363598     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.124.6.2087     Document Type: Article

References (31)

1. Hughes JD, Rubin LJ. Primary pulmonary hypertension: an analysis of 28 cases and a review of the literature. Medicine (Baltimore) 1986; 65:56-72
2. Rich S. Primary pulmonary hypertension. Prog Cardiovasc Dis 1988; 31:205-238
3. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987; 107:216-223
4. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115:343-359
5. Reeves JT, Groves BM, Turkevich D. The case for treatment of selected patients with primary pulmonary hypertension. Am Rev Respir Dis 1986; 134:342-346
6. Weir EK, Rubin LJ, Ayres SM, et al. The acute administration of vasodilators in primary pulmonary hypertension: experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. Am Rev Respir Dis 1989; 140:162.3-1630
7. Rich S, Brundage BH. High-dose calcium channel-blocking therapy for pulmonary arterial pressure and regression in right ventricular hypertrophy. Circulation 1987; 76:135-141
8. Rich S, Kaufmann E, Levy PS. The effect of high closes of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327:76-81
9. Rubin LG, Nicod P, Hillis LD, et al. Treatment of primary pulmonary hypertension with nifedipine: a hemodynamic and scintigraphic evaluation. Ann Intern Med 1983; 99:433-438
10. D'Alonzo GE, Gianotti L, Dantzker DR. Noninvasive assessment of hemodynamic improvement during chronic vasodilator therapy in obliterative pulmonary hypertension. Am Rev Respir Dis 1986; 133:380-384
11. Chan NS, McLay J, Kenmure AC. Reversibility of primary pulmonary hypertension during six years of treatment with oral diazoxide. Br Heart J 1987; 57:207-209
12. Barst RJ. Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension. Chest 1986; 98:497-503
13. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70:580-587
14. Morgan JM, Griffiths M, du Bois RM, et al. Hypoxic pulmonary vasoconstriction in systemic sclerosis and primary pulmonary hypertension. Chest 1991; 99:551-556
15. Reitz BA, Wallwork JL, Hunt SA, et al. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med 1982; 306:557-564
16. Pasque MK, Trulock EP, Kaiser LR, et al. Single lung transplantation for pulmonary hypertension: three-month hemodynamic follow-up. Circulation 1991; 84:2275-2279
17. Glanville AR, Burke CM, Theodore J, et al. Primary pulmonary hypertension: length of survival in patients referred for heart-lung transplantation. Chest 1987; 91:675-681
18. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making 1983; 3:419-458
19. Rich S. Primary pulmonary hypertension: executive summary from the world symposium. Geneva, Switzerland: World Health Organization, 1998
20. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med, 2002; 346:896-903
21. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334:296-302
22. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000; 161:487-492
23. Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994; 121:409-415
24. Rhodes J, Barst RJ, Garofano RP, et al. Hemodynamic correlates of exercise function in patients with primary pulmonary hypertension. J Am Coll Cardiol 1991; 18:1738-1744
25. Janicki JS, Weber KT, Likoff MJ, et al. Exercise testing to evaluate patients with pulmonary vascular disease. Am Rev Respir Dis 1984; 129:93-95
26. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary artery hypertension. Am J Respir Crit Care Med 2002; 165:800-804
27. The EuroQol Group. EuroQol: A new facility for the measurement of health related quality of life. Health Policy 1990; 16:199-208
28. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35:1095-1108
29. Drug topics red book. Oradell, NJ: Medical Economics Co, 2002
30. Practice Management Information Corporation. Physician fees: a comprehensive guide for fee schedule review and management. Los Angeles, CA: Practice Management Information Corporation, 1996
31. US Department of Labor. Consumer price index, medical care portion. Available at: http://www.bls.gov/cpi/home.htm. Accessed November 5, 2003.